← Back to Search

Antisense Oligonucleotide

STP705 for Basal Cell Carcinoma

Phase 2
Waitlist Available
Led By Mark Nestor, MD, PhD
Research Sponsored by Sirnaomics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights

Study Summary

This trial is testing a new drug, STP705, to see if it is safe and effective in treating basal cell carcinoma. The study will also look at biomarkers that are common in the formation of BCC to see if the drug has an effect on them.

Eligible Conditions
  • Basal Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of participants with histological clearance of treated basal cell carcinoma lesion at the End of Treatment (EOT)
Secondary outcome measures
Change in clinical diameter of the treated basal cell carcinoma lesion over the 6 week treatment period

Trial Design

7Treatment groups
Experimental Treatment
Group I: Cohort G: STP705 320 μg doseExperimental Treatment1 Intervention
Cohort G: STP705 320 μg dose, localized injection, given once a week for 6 weeks
Group II: Cohort F: STP705 240 μg doseExperimental Treatment1 Intervention
Cohort F: STP705 240 μg dose, localized injection, given once a week for 6 weeks
Group III: Cohort E: STP705 180 μg doseExperimental Treatment1 Intervention
Cohort E: STP705 180 μg dose, localized injection, given once a week for 6 weeks
Group IV: Cohort D: STP705 120 μg doseExperimental Treatment1 Intervention
Cohort D: STP705 120 μg dose, localized injection, given once a week for 6 weeks
Group V: Cohort C: STP705 90 μg doseExperimental Treatment1 Intervention
Cohort C: STP705 90 μg dose, localized injection, given once a week for 6 weeks
Group VI: Cohort B: STP705 60 μg doseExperimental Treatment1 Intervention
Cohort B: STP705 60 μg dose, localized injection, given once a week for 6 weeks
Group VII: Cohort A: STP705 30 μg doseExperimental Treatment1 Intervention
Cohort A: STP705 30 μg dose, localized injection, given once a week for 6 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
STP705
2022
Completed Phase 2
~180

Find a Location

Who is running the clinical trial?

SirnaomicsLead Sponsor
11 Previous Clinical Trials
305 Total Patients Enrolled
Amarex Clinical ResearchOTHER
26 Previous Clinical Trials
1,650 Total Patients Enrolled
Mark Nestor, MD, PhDPrincipal InvestigatorCenter for Clinical and Cosmetic Research
2 Previous Clinical Trials
79 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
2020. "Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04669808.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top